A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men
Objective: The study aimed to explore the bioequivalence of a proposed biosimilar BAT1806 to its reference products marketed in the EU and US (RoActemra-EU and Actemra-US) among healthy Chinese men. The tolerance, immunogenicity, and pharmacokinetics (PK) of the three drugs were also investigated.Me...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2021-01-01
|
| Serier: | Frontiers in Pharmacology |
| Fag: | |
| Online adgang: | https://www.frontiersin.org/articles/10.3389/fphar.2020.609522/full |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
